Compare Ferrari NV (RACE) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Ferrari NV trades at $391.01 (market cap $67.35B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Ferrari NV and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) are close in size by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| RACE | TAK | |
|---|---|---|
Market Cap | $67.35B | $58.74B |
Volume | 390,618 | 3,110,994 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $19.05 |
52-Week Low | $314.63 | $13.23 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $69.22B | $86.65B |
Dividend Yield | 1.09% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $386.39, down slightly by 0.03% today. The stock shows strong fundamentals with consistent earnings beats (Q4 2025: $2.49 vs. $2.44 expected, Q1 2026: $2.73 vs. $2.70 expected, Q2 2026: $2.99 vs. $2.83 expected) and robust profitability (net margin 22.25%, ROE 45.45%). Technical indicators are bearish overall, with the current price near support at $385. Recent news highlights a share buyback program and partnership with Rakuten effective January 2027.
Outlook: Analyst consensus is bullish with a $462.75 price target (73.69% buy ratings). Opportunities include strong brand equity, margin expansion, and strategic initiatives. Risks involve high valuation multiples (P/E 37.19, P/S 8.25), economic sensitivity, and execution of growth plans. The stock offers growth potential but requires monitoring of valuation and market conditions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
